Twist Bioscience Corp (NASDAQ:TWST) Receives Consensus Rating of “Buy” from Brokerages

Twist Bioscience Corp (NASDAQ:TWST) has been given an average recommendation of “Buy” by the six analysts that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $26.33.

Several research analysts recently commented on the stock. Evercore ISI assumed coverage on shares of Twist Bioscience in a research note on Friday, May 31st. They issued an “outperform” rating and a $26.66 target price on the stock. ValuEngine raised shares of Twist Bioscience from a “hold” rating to a “buy” rating in a research note on Thursday. Finally, Zacks Investment Research downgraded shares of Twist Bioscience from a “buy” rating to a “hold” rating in a research note on Wednesday, May 8th.

Shares of TWST stock traded down $1.28 during trading hours on Thursday, hitting $32.44. 662,800 shares of the company’s stock were exchanged, compared to its average volume of 219,175. The stock has a market capitalization of $1.02 billion and a P/E ratio of -1.27. Twist Bioscience has a 12-month low of $12.38 and a 12-month high of $35.95. The stock has a 50 day simple moving average of $29.34. The company has a quick ratio of 6.27, a current ratio of 6.51 and a debt-to-equity ratio of 0.05.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Tuesday, April 30th. The company reported ($0.93) EPS for the quarter, topping the consensus estimate of ($1.03) by $0.10. The firm had revenue of $13.56 million during the quarter, compared to analysts’ expectations of $11.88 million. On average, sell-side analysts anticipate that Twist Bioscience will post -3.65 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Citigroup Inc. bought a new stake in Twist Bioscience in the fourth quarter valued at $31,000. American International Group Inc. bought a new stake in Twist Bioscience in the fourth quarter valued at $77,000. Deutsche Bank AG bought a new stake in Twist Bioscience in the fourth quarter valued at $151,000. Asymmetry Capital Management L.P. bought a new stake in Twist Bioscience in the first quarter valued at $550,000. Finally, D. E. Shaw & Co. Inc. bought a new stake in Twist Bioscience in the fourth quarter valued at $1,039,000. 18.50% of the stock is currently owned by institutional investors.

About Twist Bioscience

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Recommended Story: What is the return on assets formula?

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.